Scienture Holdings, Inc. (NASDAQ:SCNX) announced on Tuesday that Arbli (losartan potassium) Oral Suspension, 10 mg/mL, has ...
Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension, at a ...
Expanded Coverage Reaches Over 100 Million Covered Lives Nationwide COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC.
COMMACK, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value ...
Scienture launches Arbli, the first FDA-approved liquid losartan, expanding hypertension treatment access across US ...
Novel oral suspension addresses critical patient safety needs for hypertension treatment for patients unable to swallow tablets U.S. losartan market totals $256M annually with 71M prescriptions, ...
BEDMINSTER, N.J.--(BUSINESS WIRE)--Nautilus Neurosciences, Inc. has completed a transaction for the sale of the U.S. and Canadian rights to CAMBIA® (diclofenac potassium for oral solution) to Depomed, ...
Stocktwits on MSN
Why Is Scienture Stock Rising Today?
Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation. ・The U.S. losartan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results